Facebook
X
LinkedIn
Forward
To Radiate or Not to Radiate? Updates to Management of Retroperitoneal Sarcoma
Retroperitoneal sarcomas (RPS), a rare subset of soft tissue sarcomas, account for 10-15% of these cases and are distinguished by their substantial size, infiltrative nature, and proximity to vital anatomical structures. These characteristics frequently lead to surgical challenges, contributing to high rates of local recurrence and a 5-year overall survival rate of only 50-60%. The STRASS 1 trial has sparked renewed debate regarding the role of preoperative radiation therapy (RT) in treating RPS, resulting in variable application of preop RT across practices. This activity provides a comprehensive update on the latest evidence and guidelines for RPS management. Participants benefit from case-based discussions of various histologic subtype of RPS led by expert surgical and radiation oncologists, gaining insights into the application of preoperative RT and surgical techniques.
Topics:
- A Surgeon's Perspective on RPS Management
Emily Z. Keung, MD, AM, FACS - Real World Updates in RPS: The Evolving Role of Radiation Therapy
Kilian E. Salerno, MD - Case-Based Discussions of RPS
Katie N. Lee, MD, PhD - Q and A
Miranda Lam, MD, MBA - Moderator
Full Panel
This activity is available from April 28, 2026, through 11:59 p.m. Eastern time on April 27, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists and surgeons.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the diagnosis, natural history, work up, management options, and outcomes for patients with RPS.
- Analyze recently published literature, including recent data and findings from the STRASS trial, to assess the role and impact of preoperative radiation therapy in managing RPS.
- Discuss multidisciplinary treatment options to optimize patient outcomes and reduce local recurrence rates in RPS cases.
Moderator:
- Miranda Lam, MD, MBA, is employed by Brigham and Women’s Hospital. Dr. Lam has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Emily Z. Keung, MD, AM, FACS, is employed by The University of Texas MD Anderson Cancer Center. Dr. Keung has no relevant financial relationship with ineligible companies to disclose.
- Kilian E. Salerno, MD, is employed by the Department of Defense and the National Cancer Institute. Dr. Salerno has no relevant financial relationship with ineligible companies to disclose.
- Katie N. Lee, MD, PhD, is employed by the Mayo Clinic. Dr. Lee has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until April 27, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.